Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)
Budha O Singh, Bikram Moirangthem, Prasan Kumar Panda, Yogesh Arvind Bahurupi, Sarama Saha, Girraj Saini, Minakshi Dhar, Mukesh Bairwa, Venkatesh Srinivasa Pai, Ankit Agarwal, Girish Sindhwani, Shailendra Handu, Ravikant
doi:10.1101/2021.06.06.21258091
Background Definitive antiviral treatment is not available for COVID-19 infection except remdesivir that even with many doubts. Various combination antivirals have been tried.
Methods A single-center, open-label, parallel-arm, stratified randomized controlled trial evaluated the therapeutic potential of hydroxychloroquine and lopinavir-ritonavir in combination with ribavirin in COVID-19. Enrolled patients in severe category were randomized into three groups: A: standard treatment, B: hydroxychloroquine+ribavirin+standard treatment, or C: lopinavir+ritonavir+ribavirin+standard treatment; while non-severe category into two groups: A: standard treatment or B: hydroxychloroquine+ribavirin. Combination antivirals was given for 10 days and followed for 28 days. The primary endpoints were safety, symptomatic and laboratory recovery of organ dysfunctions, and time to SARS-CoV-2 RT-PCR negative report.
Results Total 111 patients randomized: 24, 23, and 24 in severe category A, B, and C respectively, and 20 in each non-severe group. Two patients receiving ribavirin experienced drug induced liver injury and another developed QT prolongation after hydroxychloroquine. In the severe category, 47.6%, 55%, and 30.09% in A, B, and C groups respectively showed symptomatic recovery compared to 93.3% and 86.7% in A and B groups respectively in the non-severe category at 72hrs (P>0.05).
Conclusions The results failed to show statistical superiority of the antiviral combination therapies to that of the standard therapy in both the severe and non-severe categories in symptomatic adult patients of COVID-19. However, results do indicate the benefit of non-standard interventional combination therapy in severe disease. Furthermore, the dose of ribavirin needs to be reconsidered in the Indian population.
Given the results of the findings of the study and availability of a variety of therapeutic approaches including novel antivirals, modifiers of the immune response, or other intrinsic pathways, antiviral combinations may have a role in improving clinical recovery in patients of COVID-19 with severe category whereas only standard therapy is required for non-severe category. Competing interests: The authors declare that they have no competing interests.
Trial registration: Funding: Non-funded. Authors' contributions: PKP conceived the trial. PKP, AB, BCS, GC, YAB designed the trial. BCS, BM, SS collected the data. All the authors are part of the trial management committee and were involved in the review, amendments, and approval of the final protocol.
References
Agarwal, Chen, Ravindran, To, Thuluvath, Gastrointestinal and Liver Manifestations of COVID-19, J Clin Exp Hepatol
Banerjee, Popoola, Shah, Ster, Quan et al., COVID-19 infection in kidney transplant recipients, Kidney Int
Bhatnagar, Murhekar, Soneja, Gupta, Giri et al., Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use, Indian J Med Res
Bikdeli, Madhavan, Jimenez, Chuich, Dreyfus et al., COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review, J Am Coll Cardiol
For, Control, Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19, US Dep Heal Hum Serv
Henry, De Oliveira, Benoit, Plebani, Lippi, Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis, Clin Chem Lab Med
Khalili, Zhu, Mak, Yan, Zhu, Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19, J Med Virol
Khalili, Zhu, Mak, Yan, Zhu, Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19, J Med Virol
Lippi, Wong, Henry, Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis, Polish Arch Intern Med
Liu, Blet, Smyth, Li, The Science Underlying COVID-19: Implications for the Cardiovascular System, Circulation
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Pan, Peto, Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, N Engl J Med,
doi:10.1056/NEJMoa2023184Sachdeva, Gianotti, Shah, Bradanini, Tosi et al., Cutaneous manifestations of COVID-19: Report of three cases and a review of literature, J Dermatol Sci
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review, JAMA -J Am Med Assoc
Schoergenhofer, Jilma, Stimpfl, Karolyi, Zoufaly, Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease, Annals of internal medicine
The, Food and Drug Administration FDA approves first treatment for COVID-19
Whittaker, Anson, Harky, Neurological Manifestations of COVID-19: A systematic review and current update, Acta Neurol Scand
Zambrano, Ellington, Strid, Galang, Oduyebo et al., Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States, MMWR Morb Mortal Wkly Rep
Zhou, Dai, Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J Antimicrob Chemother
{ 'institution': [{'name': 'medRxiv'}],
'indexed': {'date-parts': [[2024, 4, 24]], 'date-time': '2024-04-24T00:17:34Z', 'timestamp': 1713917854572},
'posted': {'date-parts': [[2021, 6, 8]]},
'group-title': 'Infectious Diseases (except HIV/AIDS)',
'reference-count': 22,
'publisher': 'Cold Spring Harbor Laboratory',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'accepted': {'date-parts': [[2021, 6, 8]]},
'abstract': '<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Definitive '
'antiviral treatment is not available for COVID-19 infection except remdesivir that even with '
'many doubts. Various combination antivirals have been '
'tried.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A single-center, '
'open-label, parallel-arm, stratified randomized controlled trial evaluated the therapeutic '
'potential of hydroxychloroquine and lopinavir-ritonavir in combination with ribavirin in '
'COVID-19. Enrolled patients in severe category were randomized into three groups: A: standard '
'treatment, B: hydroxychloroquine+ribavirin+standard treatment, or C: '
'lopinavir+ritonavir+ribavirin+standard treatment; while non-severe category into two groups: '
'A: standard treatment or B: hydroxychloroquine+ribavirin. Combination antivirals was given '
'for 10 days and followed for 28 days. The primary endpoints were safety, symptomatic and '
'laboratory recovery of organ dysfunctions, and time to SARS-CoV-2 RT-PCR negative '
'report.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Total 111 '
'patients randomized: 24, 23, and 24 in severe category A, B, and C respectively, and 20 in '
'each non-severe group. Two patients receiving ribavirin experienced drug induced liver injury '
'and another developed QT prolongation after hydroxychloroquine. In the severe category, '
'47.6%, 55%, and 30.09% in A, B, and C groups respectively showed symptomatic recovery '
'compared to 93.3% and 86.7% in A and B groups respectively in the non-severe category at '
'72hrs '
'(P>0.05).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The '
'results failed to show statistical superiority of the antiviral combination therapies to that '
'of the standard therapy in both the severe and non-severe categories in symptomatic adult '
'patients of COVID-19. However, results do indicate the benefit of non-standard interventional '
'combination therapy in severe disease. Furthermore, the dose of ribavirin needs to be '
'reconsidered in the Indian population.</jats:p></jats:sec>',
'DOI': '10.1101/2021.06.06.21258091',
'type': 'posted-content',
'created': {'date-parts': [[2021, 6, 8]], 'date-time': '2021-06-08T16:55:35Z', 'timestamp': 1623171335000},
'source': 'Crossref',
'is-referenced-by-count': 1,
'title': 'Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized '
'controlled trial (SEV COVID Trial)',
'prefix': '10.1101',
'author': [ {'name': 'SEV COVID trial group', 'sequence': 'first', 'affiliation': []},
{'given': 'Budha O', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bikram', 'family': 'Moirangthem', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-3008-7245',
'authenticated-orcid': False,
'given': 'Prasan Kumar',
'family': 'Panda',
'sequence': 'additional',
'affiliation': []},
{'given': 'Yogesh Arvind', 'family': 'Bahurupi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sarama', 'family': 'Saha', 'sequence': 'additional', 'affiliation': []},
{'given': 'Girraj', 'family': 'Saini', 'sequence': 'additional', 'affiliation': []},
{'given': 'Minakshi', 'family': 'Dhar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mukesh', 'family': 'Bairwa', 'sequence': 'additional', 'affiliation': []},
{'given': 'Venkatesh Srinivasa', 'family': 'Pai', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ankit', 'family': 'Agarwal', 'sequence': 'additional', 'affiliation': []},
{'given': 'Girish', 'family': 'Sindhwani', 'sequence': 'additional', 'affiliation': []},
{'given': 'Shailendra', 'family': 'Handu', 'sequence': 'additional', 'affiliation': []},
{'family': 'Ravikant', 'sequence': 'additional', 'affiliation': []}],
'member': '246',
'reference': [ { 'key': '2021061004300790000_2021.06.06.21258091v1.1',
'first-page': '1',
'volume': '2019',
'author': 'Centers for Disease Control and Prevention',
'year': '2020',
'journal-title': 'Evidence used to update the list of underlying medical conditions that '
'increase a person’s risk of severe illness from COVID-19. US Dep Heal '
'Hum Serv'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.kint.2020.03.018'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.3',
'doi-asserted-by': 'publisher',
'DOI': '10.15585/mmwr.mm6944e3'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.4',
'doi-asserted-by': 'publisher',
'DOI': '10.1111/ane.13266'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.5',
'doi-asserted-by': 'publisher',
'DOI': '10.1515/cclm-2020-0369'},
{ 'issue': '3',
'key': '2021061004300790000_2021.06.06.21258091v1.6',
'doi-asserted-by': 'crossref',
'first-page': '263',
'DOI': '10.1016/j.jceh.2020.03.001',
'article-title': 'Gastrointestinal and Liver Manifestations of COVID-19',
'volume': '10',
'year': '2020',
'journal-title': 'J Clin Exp Hepatol'},
{ 'issue': '2',
'key': '2021061004300790000_2021.06.06.21258091v1.7',
'doi-asserted-by': 'crossref',
'first-page': '75',
'DOI': '10.1016/j.jdermsci.2020.04.011',
'article-title': 'Cutaneous manifestations of COVID-19: Report of three cases and a '
'review of literature',
'volume': '98',
'year': '2020',
'journal-title': 'J Dermatol Sci'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.8',
'doi-asserted-by': 'publisher',
'DOI': '10.1161/CIRCULATIONAHA.120.047549'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.9',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S0735-1097(20)33577-4'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.10',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41421-020-0156-0'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.11',
'unstructured': 'Indian Council of Medical Research [Internet]. Advisory on the use of '
'Hydroxychloroquin as prophylaxis for SARS-CoV-2 infection [Internet]. '
'2020. p. 1–3. Available from: '
'https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf'},
{ 'issue': '7',
'key': '2021061004300790000_2021.06.06.21258091v1.12',
'doi-asserted-by': 'crossref',
'first-page': '1667',
'DOI': '10.1093/jac/dkaa114',
'article-title': 'COVID-19: a recommendation to examine the effect of hydroxychloroquine '
'in preventing infection and progression',
'volume': '75',
'year': '2020',
'journal-title': 'J Antimicrob Chemother'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.13',
'doi-asserted-by': 'crossref',
'first-page': '670',
'DOI': '10.7326/M20-1550',
'article-title': 'Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized '
'With Coronavirus Disease 2019 (COVID-19)',
'volume': '173',
'year': '2020',
'journal-title': 'Annals of internal medicine'},
{ 'issue': '2 & 3',
'key': '2021061004300790000_2021.06.06.21258091v1.14',
'first-page': '184',
'article-title': 'Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus '
'disease 2019 patients in India: Protocol for restricted public health '
'emergency use',
'volume': '151',
'year': '2020',
'journal-title': 'Indian J Med Res'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.15',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/jmv.25798'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.16',
'first-page': '784',
'article-title': 'Landscape analysis of COVID therapeutics as 21 March 2020',
'volume': '18',
'year': '2020',
'journal-title': 'Pharmacological Research'},
{ 'issue': '4',
'key': '2021061004300790000_2021.06.06.21258091v1.17',
'first-page': '304',
'article-title': 'Hypertension in patients with coronavirus disease 2019 (COVID-19): A '
'pooled analysis',
'volume': '130',
'year': '2020',
'journal-title': 'Polish Arch Intern Med'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.18',
'unstructured': 'COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) '
'Treatment Guidelines. National Institutes of Health. Available at '
'https://www.covid19treatmentguidelines.nih.gov/.'},
{ 'issue': '18',
'key': '2021061004300790000_2021.06.06.21258091v1.19',
'first-page': '1824',
'article-title': 'Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A '
'Review',
'volume': '323',
'year': '2020',
'journal-title': 'JAMA - J Am Med Assoc'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.20',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/jmv.25798'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.21',
'unstructured': 'The U.S. Food and Drug Administration FDA approves first treatment for '
'COVID-19. 2020. '
'https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 '
'accessed May 30th, 2021.'},
{ 'key': '2021061004300790000_2021.06.06.21258091v1.22',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2023184'}],
'container-title': [],
'original-title': [],
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.06.06.21258091',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 4, 23]],
'date-time': '2024-04-23T16:25:18Z',
'timestamp': 1713889518000},
'score': 1,
'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.06.06.21258091'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 6, 8]]},
'references-count': 22,
'URL': 'http://dx.doi.org/10.1101/2021.06.06.21258091',
'relation': { 'is-preprint-of': [ { 'id-type': 'doi',
'id': '10.2147/cpaa.s325083',
'asserted-by': 'subject'}]},
'subject': [],
'published': {'date-parts': [[2021, 6, 8]]},
'subtype': 'preprint'}
